AngioDynamics, Inc. (ANGO)

Delcath Systems (NASDAQ: DCTH - Get Free Report) and AngioDynamics (NASDAQ: ANGO - Get Free Report) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their analyst recommendations, risk, earnings, institutional ownership, valuation, dividends and profitability. Valuation and Earnings This table compares Delcath Systems

Representative Debbie Wasserman Schultz (D-Florida) recently sold shares of Innovex International, Inc. (NYSE: INVX). In a filing disclosed on December 08th, the Representative disclosed that they had sold between $1,001 and $15,000 in Innovex International stock on November 25th. Representative Debbie Wasserman Schultz also recently made the following trade(s): Sold $1,001 - $15,000 in shares of

AXQ Capital LP boosted its holdings in shares of AngioDynamics, Inc. (NASDAQ: ANGO) by 34.7% during the undefined quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 27,231 shares of the medical instruments supplier's stock after buying an additional 7,011 shares during the quarter. AXQ

ANGO benefits from NanoKnife, clinical milestones and a balanced portfolio despite tariff headwinds.

AngioDynamics, Inc. ( ANGO ) UBS Global Healthcare Conference 2025 November 10, 2025 8:00 AM EST Company Participants James Clemmer - CEO, President & Director Stephen Trowbridge - Executive VP & CFO Conference Call Participants Danielle Antalffy - UBS Investment Bank, Research Division Steven Lichtman - Oppenheimer & Co. Inc., Research Division Presentation Danielle Antalffy UBS Investment Bank, Research Division Well, good morning, everyone. Thank you for joining us.

LATHAM, N.Y.--(BUSINESS WIRE)--AngioDynamics, Inc. (NASDAQ: ANGO), a medical technology company focused on restoring healthy blood flow in the body's vascular system, expanding cancer treatment options and improving patient quality of life, today announced, that Jim Clemmer, President and Chief Executive Officer, and Stephen Trowbridge, Executive Vice President and Chief Financial Officer, will participate in a fireside chat at the UBS Global Healthcare Conference at 8:00 a.m. ET on Monday, Nov.

LATHAM, N.Y.--(BUSINESS WIRE)--AngioDynamics, Inc. (NASDAQ: ANGO), a medical technology company focused on restoring healthy blood flow in the body's vascular system, expanding cancer treatment options and improving patient quality of life, today announced that its NanoKnife System has been selected as one of TIME's 2025 Best Inventions. The annual list celebrates groundbreaking products and technologies that are transforming how people live, work, and receive care. For the past 25 years, TIME'.

AngioDynamics posts narrower-than-expected Q1 loss, 12% revenue growth and margin gains; it also raises FY26 sales outlook, sending shares higher.

AngioDynamics, Inc. remains a Buy, trading at a steep discount to peers despite double-digit MedTech growth and improving margins. ANGO's Med Tech division now drives 47% of sales, with strong performance from Auryon, AlphaVac, AngioVac, and NanoKnife products. Gross margin improved to 55.3%, operating costs are under control, and management expects positive cash flow and raised guidance for FY 2026.

AngioDynamics (ANGO 7.00%) stock soared 10.5% through 11:25 a.m. ET Thursday after beating on "earnings" (sort of) this morning.

AngioDynamics, Inc. (NASDAQ:ANGO ) Q1 2026 Earnings Call October 2, 2025 8:00 AM EDT Company Participants James Clemmer - CEO, President & Director Stephen Trowbridge - Executive VP & CFO Conference Call Participants John Young - Canaccord Genuity Corp., Research Division Frank Takkinen - Lake Street Capital Markets, LLC, Research Division Eduardo Martinez-Montes - H.C. Wainwright & Co, LLC, Research Division Presentation Operator Good morning, and welcome to the AngioDynamics Fiscal Year 2026 First Quarter Earnings Call.

U.S. stocks traded higher this morning, with the Nasdaq Composite gaining more than 100 points.

AngioDynamics (ANGO) came out with a quarterly loss of $0.1 per share versus the Zacks Consensus Estimate of a loss of $0.14. This compares to a loss of $0.11 per share a year ago.

LATHAM, N.Y.--(BUSINESS WIRE)--AngioDynamics, Inc. (NASDAQ: ANGO), a leading and transformative medical technology company focused on restoring healthy blood flow in the body's vascular system, expanding cancer treatment options, and improving quality of life for patients, today announced financial results for the first quarter of fiscal year 2026, which ended August 31, 2025. Fiscal Year 2026 First Quarter Highlights   Quarter Ended August 31, 2025 Pro Forma* YoY Growth Net Sales $75.7 million.